DDX19A

Across TCGA pan-cancer cohorts, DDX19A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DDX19A data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DDX19A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DDX19A expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where DDX19A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.432	0.925	.047	3	view →
LSCC	DFS	Median	II,III,IV	0.962	0.871	.048	2	view →
PDAC	DFS	Quartile	III,IV	0.834	0.315	.013	2	view →
HNSC	OS	Median	IV	0.764	0.929	.040	1	view →
CCRCC	OS	Median	All	0.784	0.900	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DDX19A–LUAD (DFS)

Open the LUAD breakdown →